Solana Beach, California-based biotechnology company, Organovo Holdings, Inc., has been grabbing attention for its unique focus on developing 3D tissues that simulate vital aspects of human diseases. Central to its 3D human tissue platform is its NovoGen Bioprinters - automated devices that allow for the production of 3D living tissues comprising mammalian cells, alongside related technologies to prepare bio-inks and print multicellular tissues with complex architecture. With a specific focus on the development of ExVive human liver tissue and ExVive human kidney tissue, the company aims to use these innovations for preclinical testing of drug compounds. Incorporated in 2007, Organovo Holdings, Inc. remains at the forefront of biotechnology research and development, with a commitment to advancing the field of 3D bioprinting.